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Summary
We reappraise the psychiatric potential of calcium channel
blockers (CCBs). First, voltage-gated calcium channels are risk
genes for several disorders. Second, use of CCBs is associated
with altered psychiatric risks and outcomes. Third, research
shows there is an opportunity for brain-selective CCBs, which
are better suited to psychiatric indications.
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Calcium channel blockers (CCBs) block voltage-gated calcium
channels (VGCCs) and have been widely used to treat hypertension
and other cardiovascular conditions for 40 years.1 Interest in the
possibility that CCBs might also have value in psychiatry, especially
bipolar disorder, goes back almost as far. This reflected several
factors, including the critical roles of ionic calcium in neuronal
function and neurotoxicity, its putative involvement in mood regu-
lation, and the calcium-modulating effects of lithium. However,
CCBs did not find an established position in the treatment of any
psychiatric disorder, and interest in the topic had dwindled by the
early 2000s.2 Nevertheless, developments over the past decade
suggest that it is premature to dismiss VGCCs and CCBs as
having no potential therapeutic value in psychiatry.3
A primer on calcium channels and CCBs
VGCCs flux calcium across excitable cell membranes.4 As shown in
Fig. 1, they comprise a pore-forming α1 subunit accompanied by β
and usually α2δ auxiliary subunits; γ subunits are also described but
are not in fact part of most VGCCs.5 VGCC nomenclature is
complex (Table 1).6 The channels are grouped into ‘types’ based
on their properties (e.g. L-type refers to large and long-lasting cur-
rents), which in turn are largely determined by the constituent α1
subunit. It is the L-type VGCCs that are the primary target of
CCBs, with CACNA1C (CaV1.2) and CACNA1D (CaV1.3) being
the main subtypes expressed in the brain, and hence of most psychi-
atric relevance.
CCBs are a structurally diverse class. The major subtypes are
benzothiazepines (e.g. diltiazem), phenylalkylamines (e.g. verap-
amil) and dihydropyridines (DHPs, which comprise the other
CCBs, including most in current use). All classes bind reversibly to
the α1 subunit; verapamil binds in the pore itself, whereas DHPs
bind to a nearby transmembrane domain to alter the shape of the
pore and thereby prevent Ca2+ flow. Among DHPs, individual
drugs show some differences, such as their relative preference for
L-type VGCC subtype, their half-life and their permeability across
the blood–brain barrier.3,6 All of these factors might affect their
use in psychiatry.
Recent VGCC and CCB developments
The most important stimulus reinvigorating psychiatric interest in
CCBs was the discovery that VGCCs are part of the genetic risk
architecture for a range of disorders. The initial report was of the
association of a polymorphism within CACNA1C in an early
genome-wide association study of bipolar disorder; the evidence
has grown to encompass genome-wide significance for several
VGCC subunits across a range of disorders (Table 1).7 There is
also some evidence for disease-associated rare variants in some
VGCCs, notably mutations in CACNA1C which cause Timothy
syndrome, a disorder characterised by arrhythmias, syndactyly
and autism.
The disease associations of VGCCs shown in Table 1 share all
the caveats of other genome-wide association study findings, such
as the very small effect size, the unidentified causal variants and
the unknown molecular correlates of the risk alleles.8 Despite the
uncertainties, VGCCs have the notable attraction that, in contrast
to most implicated psychiatric genes, they are known to be ‘drug-
gable’. This is not just because of CCBs but due to other licensed
drugs such as gabapentin and pregabalin, which are ligands of the
α2δ subunit, and lamotrigine and topiramate, which block VGCCs
among other actions. Hence, VGCCs are the poster child for
showing whether and how genomic discoveries can lead to novel
psychiatric treatments, a promise often made but one which
involves a long and largely uncharted path.9 Another implication
of the genomic findings is that response to CCBs might be
The British Journal of Psychiatry (2019)
Page 1 of 4. doi: 10.1192/bjp.2019.157
1
influenced by VGCC genotype, although this has not been tested
other than in a pilot study.10
In addition to the statistical associations with psychiatric disorders,
growing evidence shows that VGCCs contribute to relevant brain phe-
notypes. Studies with genetically modified rodents reveal that L-type
VGCCs affect domains of cognition, mood, emotion and reward.11
Some effects are developmentally specific and accompanied by altera-
tions in synaptic plasticity and neurogenesis.12,13 There is also
increasing evidence that centrally acting CCBs affect similar processes,
including forms of memory and plasticity.14 In humans, VGCC risk
alleles are associated with a range of alterations in brain structure,
task performance and in patterns of neural activation.15 However,
the findings in both rodents and humans are varied, and their inter-
pretation complex. As a result, although the literature provides increas-
ingly strong support for a role of L-type VGCCs in many aspects of
brain and behaviour, the details and implications remain unclear.
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Fig. 1 Voltage-gated calcium channel topology. The α1 subunit is a large transmembrane protein with intracellular amino (N) and carboxyl (C)
termini. It has four voltage-sensing domains (I–IV), each of which spans the plasma membrane via six helices (S1–S6). The smaller β (green) and
α2δ (blue/yellow) auxiliary subunits are also shown. The inset illustrates how the α1 subunit folds to produce the pore through which calcium
ions pass when the membrane is depolarised.
Table 1 Voltage-gated calcium channel nomenclature and genetic associations to psychiatric disorders
Subunit type Channel type Drug target for Subunit name Channel namea Gene symbol GWAS association Rare variants
Alpha (α1) L-type All CCBs α1S CaV1.1 CACNA1S XD Scz
α1C CaV1.2 CACNA1C BD, Scz, ASD, XD ASD, BD, Scz
α1D CaV1.3 CACNA1D XD ASD, BD
α1F CaV1.4 CACNA1F
P-/Q-type α1A CaV2.1 CACNA1A
N-type α1B CaV2.2 CACNA1B BD, Scz
R-type Lamotrigine, topiramate α1E CaV2.3 CACNA1E MDD, XD
T-type Some CCBs, e.g. nimodipine α1G CaV3.1 CACNA1G
α1H CaV3.2 CACNA1H ASD, Scz
α1I CaV3.3 CACNA1I ASD, Scz
Beta (β) β1 CACNB1
β2 CACNB2 Scz ASD
β3 CACNB3
β4 CACNB4 Scz
Alpha2delta (α2δ) Pregabalin, gabapentin α2δ1 CACNA2D1 MDD Scz
Pregabalin, gabapentin α2δ2 CACNA2D2 XD Scz
α2δ3 CACNA2D3 ASD
α2δ4 CACNA2D4 XD Scz
GWAS, genome-wide association study; CCB, calcium channel blockers; XD, cross-diagnostic (schizophrenia/bipolar disorder/major depressive disorder/autism spectrum disorder/
attention-deficit hyperactivity disorder); Scz, schizophrenia; BD, bipolar disorder; ASD, autism spectrum disorder; MDD, major depressive disorder.
a. Channel name defined by α1 subunit, so terminology does not apply to β or α2δ subunits.
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An obvious counter to the genomically driven proposal that
VGCCs may be good psychiatric drug targets is that, as noted
above, CCBs have already been tested and found largely ineffective
in several disorders. However, most of the studies used the first gen-
eration of drugs, especially verapamil.2,3 Compared to the DHPs,
these drugs are less selective and have poorer or unknown perme-
ability across the blood–brain barrier. Thus it can be argued that
CCBs have not been critically tested for psychiatric indications.
Moreover, the studies were limited in terms of sophistication,
breadth and scale. In particular, pursuing the genomic logic, since
VGCCs contribute to a range of disorders, CCBs may have value
in treating transdiagnostic features such as mood instability, cogni-
tive dysfunction and circadian disruption. To address these possibil-
ities, Atkinson and colleagues16 are investigating the effect of
nicardipine – a brain-penetrant DHP – on mood, sleep and cogni-
tion. The study also assesses nicardipine’s effects on brain activity,
using functional MRI and magnetoencephalography, as well as
leucocyte calcium channel expression and calcium flux.
The extensive cardiovascular prescribing of CCBs allows for
pharmacoepidemiological studies to assess whether their use is asso-
ciated with an altered risk or course of neuropsychiatric disorders.
Hayes et al17 recently showed that, among patients with psychosis,
rates of psychiatric admission and self-harm were 10–20% lower
during periods of CCB treatment. The design rules out confounding
by indication and no similar benefits were seen for thiazide diuretics
or for non-psychiatric admissions, suggesting a degree of specificity.
There is also meta-analytic evidence that CCB use is associated with
20–30% lower risks of developing dementia and Parkinson’s
disease.18 However, there are also preliminary data suggesting
higher admission rates for depression in people taking CCBs,19 a
finding requiring further evaluation. Nevertheless, the epidemio-
logical data tentatively suggest that CCBs may have beneficial pre-
ventative or ameliorating effects on a range of neuropsychiatric
disorders. It is unclear whether the postulated benefits are mediated
directly via central VGCC antagonism or indirectly via cardiovascu-
lar effects or other mechanisms, such as lowering oxidative stress or
inducing autophagy.20 Regardless, the data provide encouragement
to conduct further psychiatric clinical trials of CCBs.
Targeting brain VGCCs
Even if some psychiatric benefits of existing CCBs have been over-
looked, these drugs are unlikely to be suitable, let alone optimal,
agents for use, in part because of their cardiovascular effects and
side-effects (e.g. headache, ankle swelling). A key advance would
be CCBs that potently target brain VGCCs but spare those in the
periphery. An opportunity to achieve this goal is provided by the
fact that VGCC genes, including those encoding the α1 subunits,
are expressed as multiple variants (‘isoforms’). Critically, some iso-
forms are more highly expressed in the brain than in the heart and
they differ in some physiological and pharmacological proper-
ties.6,18 Until recently, the psychiatric relevance of these data was
limited. First, they pertained to rodents and could not confidently
be extrapolated to humans. Second, most isoforms were simply
based on the inclusion or exclusion of individual exons; given that
some VGCC genes contain over 50 exons, it was difficult to deter-
mine the structure of full-length transcripts or, therefore, the full-
length protein. Third, many additional isoforms likely existed but
had not been detected by the available methodologies.
These limitations can now be overcome utilising new technolo-
gies. By using long-range polymerase chain reaction and Nanopore
sequencing, Clark et al21 found that CACNA1C is expressed in
human brain as multiple messenger RNA isoforms, most of which
had not been reported (in humans or in rodents), and with
several being abundant and affecting key functional domains of
the channel. The experimental design strongly implies that the var-
iants are all muchmore abundant in the brain than in the heart. This
emerging evidence supports the existence of brain-enriched VGCC
isoforms, providing targets for novel CCBs with the potential for
reduced peripheral effects. Assuming the novel drugs were also
penetrant of the blood–brain barrier, they would finally allow the
value of CCBs for psychiatric indications to be tested critically.
Conclusions
Until positive results from randomised clinical trials are reported,
CCBs cannot be considered to have any role in psychiatry.
However, the recent developments cumulatively and markedly
strengthen the candidacy of VGCCs as therapeutic targets and
encourage the development of drugs with selectivity for brain-
enriched isoforms. As noted, it is primarily the genomic findings
that have rekindled psychiatric interest in VGCCs. By the same
token, it will be of considerable interest to see how the possibility
that they are therapeutic targets develops: success would serve as
an important proof of principle that psychiatric genomics
can pay off therapeutically. Failure would still be valuable if
lessons are learned regarding the strategies and approaches that
work versus those that do not. The only unqualified failure for
psychiatry will be if the science is done inadequately, or not
done at all.
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